A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
REGULATORY
MOF Generic Target, Reference Pricing Rollout “Impossible”: LDP Panel
A healthcare committee of the ruling Liberal Democratic Party (LDP) agreed on June 18 that it would be “impossible” to set a generic share target of 80% by the end of FY2017 or introduce a so-called reference pricing system as…
To read the full story
Related Article
- Shiozaki’s Pitch on 80% Generic Target by FY2020 Fails to Resonate
June 11, 2015
- MOF Panel Recommends Generic Target of 80% by FY2017-End
June 2, 2015
- MHLW to Set Generic Share Target of 80% by FY2020-End: Shiozaki
May 27, 2015
- Govt Panel Members Renew Call for Annual Drug Price Cuts, Amari Says Conclusion Out after 2016-2018 Consecutive Revisions
May 20, 2015
- Some LDP Members Keen to Tackle Kampo NHI Price Problem
January 21, 2015
REGULATORY
- MHLW Eyes 2 Biz Models as It Pushes Generic Industry Shakeup: Minister
January 23, 2025
- Draft Bill to Amend PMD Act Up for LDP Review on Jan. 27
January 23, 2025
- How’s Drug Discovery Fund Different from AMED? LDP Member Says It’s Too Early to Submit Legislation
January 22, 2025
- Astellas’ Xtandi on 2nd Drug List Up for IRA Price Negotiations
January 21, 2025
- Lixiana Label Expansion on Agenda for MHLW Panel Session on Jan. 31
January 20, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…